51
|
Aaltonen N, Kedzierska E, Orzelska-Górka J, Lehtonen M, Navia-Paldanius D, Jakupovic H, Savinainen JR, Nevalainen T, Laitinen JT, Parkkari T, Gynther M. In Vivo Characterization of the Ultrapotent Monoacylglycerol Lipase Inhibitor {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048). J Pharmacol Exp Ther 2016; 359:62-72. [PMID: 27451409 DOI: 10.1124/jpet.116.233114] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2016] [Accepted: 07/08/2016] [Indexed: 02/04/2023] Open
Abstract
Monoacylglycerol lipase (MAGL) is a serine hydrolase that acts as a principal degradative enzyme for the endocannabinoid 2-arachidonoylglycerol (2-AG). In addition to terminating the signaling function of 2-AG, MAGL liberates arachidonic acid to be used as a primary source for neuroinflammatory prostaglandin synthesis in the brain. MAGL activity also contributes to cancer pathogenicity by producing precursors for tumor-promoting bioactive lipids. Pharmacological inhibitors of MAGL provide valuable tools for characterization of MAGL and 2-AG signaling pathways. They also hold great therapeutic potential to treat several pathophysiological conditions, such as pain, neurodegenerative disorders, and cancer. We have previously reported piperidine triazole urea, {4-[bis-(benzo[d][1,3]dioxol-5-yl)methyl]-piperidin-1-yl}(1H-1,2,4-triazol-1-yl)methanone (JJKK-048), to be an ultrapotent and highly selective inhibitor of MAGL in vitro. Here, we characterize in vivo effects of JJKK-048. Acute in vivo administration of JJKK-048 induced a massive increase in mouse brain 2-AG levels without affecting brain anandamide levels. JJKK-048 appeared to be extremely potent in vivo. Activity-based protein profiling revealed that JJKK-048 maintains good selectivity toward MAGL over other serine hydrolases. Our results are also the first to show that JJKK-048 promoted significant analgesia in a writhing test with a low dose that did not cause cannabimimetic side effects. At a high dose, JJKK-048 induced analgesia both in the writhing test and in the tail-immersion test, as well as hypomotility and hyperthermia, but not catalepsy.
Collapse
Affiliation(s)
- Niina Aaltonen
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| | - Ewa Kedzierska
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| | - Jolanta Orzelska-Górka
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| | - Marko Lehtonen
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| | - Dina Navia-Paldanius
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| | - Hermina Jakupovic
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| | - Juha R Savinainen
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| | - Tapio Nevalainen
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| | - Jarmo T Laitinen
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| | - Teija Parkkari
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| | - Mikko Gynther
- School of Medicine, Institute of Biomedicine/Physiology (N.A., D.N.-P., H.J., J.R.S., J.T.L.), and School of Pharmacy, (M.L., T.N., T.P., M.G.), University of Eastern Finland, Kuopio, Finland; and Department of Pharmacology and Pharmacodynamics, Faculty of Pharmacy with Division of Medical Analytics, Medical University of Lublin, Lublin, Poland (E.K., J.O.-G.)
| |
Collapse
|
52
|
Ceccarini J, Weltens N, Ly HG, Tack J, Van Oudenhove L, Van Laere K. Association between cerebral cannabinoid 1 receptor availability and body mass index in patients with food intake disorders and healthy subjects: a [(18)F]MK-9470 PET study. Transl Psychiatry 2016; 6:e853. [PMID: 27404285 PMCID: PMC5545708 DOI: 10.1038/tp.2016.118] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/01/2016] [Accepted: 04/25/2016] [Indexed: 01/15/2023] Open
Abstract
Although of great public health relevance, the mechanisms underlying disordered eating behavior and body weight regulation remain insufficiently understood. Compelling preclinical evidence corroborates a critical role of the endocannabinoid system (ECS) in the central regulation of appetite and food intake. However, in vivo human evidence on ECS functioning in brain circuits involved in food intake regulation as well as its relationship with body weight is lacking, both in health and disease. Here, we measured cannabinoid 1 receptor (CB1R) availability using positron emission tomography (PET) with [(18)F]MK-9470 in 54 patients with food intake disorders (FID) covering a wide body mass index (BMI) range (anorexia nervosa, bulimia nervosa, functional dyspepsia with weight loss and obesity; BMI range=12.5-40.6 kg/m(2)) and 26 age-, gender- and average BMI-matched healthy subjects (BMI range=18.5-26.6 kg/m(2)). The association between regional CB1R availability and BMI was assessed within predefined homeostatic and reward-related regions of interest using voxel-based linear regression analyses. CB1R availability was inversely associated with BMI in homeostatic brain regions such as the hypothalamus and brainstem areas in both patients with FID and healthy subjects. However, in FID patients, CB1R availability was also negatively correlated with BMI throughout the mesolimbic reward system (midbrain, striatum, insula, amygdala and orbitofrontal cortex), which constitutes the key circuit implicated in processing appetitive motivation and hedonic value of perceived food rewards. Our results indicate that the cerebral homeostatic CB1R system is inextricably linked to BMI, with additional involvement of reward areas under conditions of disordered body weight.
Collapse
Affiliation(s)
- J Ceccarini
- Division of Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
| | - N Weltens
- Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium
| | - H G Ly
- Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium
| | - J Tack
- Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium
- Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
| | - L Van Oudenhove
- Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders, KU Leuven, Leuven, Belgium
- Liaison Psychiatry, University Psychiatric Center Campus Gasthuisberg, University Hospitals Leuven, Leuven, Belgium
| | - K Van Laere
- Division of Nuclear Medicine and Molecular Imaging, Department of Imaging and Pathology, University Hospitals Leuven, KU Leuven, Leuven, Belgium
- Leuven Institute for Neurobiology and Disease, KU Leuven, Leuven, Belgium
| |
Collapse
|
53
|
Bow EW, Rimoldi JM. The Structure-Function Relationships of Classical Cannabinoids: CB1/CB2 Modulation. PERSPECTIVES IN MEDICINAL CHEMISTRY 2016; 8:17-39. [PMID: 27398024 PMCID: PMC4927043 DOI: 10.4137/pmc.s32171] [Citation(s) in RCA: 64] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 02/17/2016] [Revised: 05/31/2016] [Accepted: 06/02/2016] [Indexed: 12/11/2022]
Abstract
The cannabinoids are members of a deceptively simple class of terpenophenolic secondary metabolites isolated from Cannabis sativa highlighted by (-)-Δ(9)-tetrahydrocannabinol (THC), eliciting distinct pharmacological effects mediated largely by cannabinoid receptor (CB1 or CB2) signaling. Since the initial discovery of THC and related cannabinoids, synthetic and semisynthetic classical cannabinoid analogs have been evaluated to help define receptor binding modes and structure-CB1/CB2 functional activity relationships. This perspective will examine the classical cannabinoids, with particular emphasis on the structure-activity relationship of five regions: C3 side chain, phenolic hydroxyl, aromatic A-ring, pyran B-ring, and cyclohexenyl C-ring. Cumulative structure-activity relationship studies to date have helped define the critical structural elements required for potency and selectivity toward CB1 and CB2 and, more importantly, ushered the discovery and development of contemporary nonclassical cannabinoid modulators with enhanced physicochemical and pharmacological profiles.
Collapse
Affiliation(s)
- Eric W. Bow
- Department of BioMolecular Sciences, Division of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS, USA
| | - John M. Rimoldi
- Department of BioMolecular Sciences, Division of Medicinal Chemistry, School of Pharmacy, University of Mississippi, University, MS, USA
| |
Collapse
|
54
|
Olmo IG, Ferreira-Vieira TH, Ribeiro FM. Dissecting the Signaling Pathways Involved in the Crosstalk between Metabotropic Glutamate 5 and Cannabinoid Type 1 Receptors. Mol Pharmacol 2016; 90:609-619. [PMID: 27338080 DOI: 10.1124/mol.116.104372] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2016] [Accepted: 06/16/2016] [Indexed: 02/06/2023] Open
Abstract
The metabotropic glutamate 5 receptor and the cannabinoid type 1 receptor are G protein-coupled receptors that are widely expressed in the central nervous system. Metabotropic glutamate 5 receptors, present at the postsynaptic site, are coupled to Gαq/11 proteins and display an excitatory response upon activation, whereas the cannabinoid type 1 receptor, mainly present at presynaptic terminals, is coupled to the Gi/o protein and triggers an inhibitory response. Recent studies suggest that the glutamatergic and endocannabinoid systems exhibit a functional interaction to modulate several neural processes. In this review, we discuss possible mechanisms involved in this crosstalk and its relationship with physiologic and pathologic conditions, including nociception, addiction, and fragile X syndrome.
Collapse
Affiliation(s)
- Isabella G Olmo
- Department of Biochemistry and Immunology, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Talita H Ferreira-Vieira
- Department of Biochemistry and Immunology, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| | - Fabiola M Ribeiro
- Department of Biochemistry and Immunology, Instituto de Ciencias Biologicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil
| |
Collapse
|
55
|
Katchan V, David P, Shoenfeld Y. Cannabinoids and autoimmune diseases: A systematic review. Autoimmun Rev 2016; 15:513-28. [DOI: 10.1016/j.autrev.2016.02.008] [Citation(s) in RCA: 87] [Impact Index Per Article: 10.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2016] [Accepted: 02/03/2016] [Indexed: 12/21/2022]
|
56
|
Wohlman IM, Composto GM, Heck DE, Heindel ND, Lacey CJ, Guillon CD, Casillas RP, Croutch CR, Gerecke DR, Laskin DL, Joseph LB, Laskin JD. Mustard vesicants alter expression of the endocannabinoid system in mouse skin. Toxicol Appl Pharmacol 2016; 303:30-44. [PMID: 27125198 DOI: 10.1016/j.taap.2016.04.014] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2016] [Revised: 04/16/2016] [Accepted: 04/20/2016] [Indexed: 12/16/2022]
Abstract
Vesicants including sulfur mustard (SM) and nitrogen mustard (NM) are bifunctional alkylating agents that cause skin inflammation, edema and blistering. This is associated with alterations in keratinocyte growth and differentiation. Endogenous cannabinoids, including N-arachidonoylethanolamine (anandamide, AEA) and 2-arachidonoyl glycerol (2-AG), are important in regulating inflammation, keratinocyte proliferation and wound healing. Their activity is mediated by binding to cannabinoid receptors 1 and 2 (CB1 and CB2), as well as peroxisome proliferator-activated receptor alpha (PPARα). Levels of endocannabinoids are regulated by fatty acid amide hydrolase (FAAH). We found that CB1, CB2, PPARα and FAAH were all constitutively expressed in mouse epidermis and dermal appendages. Topical administration of NM or SM, at concentrations that induce tissue injury, resulted in upregulation of FAAH, CB1, CB2 and PPARα, a response that persisted throughout the wound healing process. Inhibitors of FAAH including a novel class of vanillyl alcohol carbamates were found to be highly effective in suppressing vesicant-induced inflammation in mouse skin. Taken together, these data indicate that the endocannabinoid system is important in regulating skin homeostasis and that inhibitors of FAAH may be useful as medical countermeasures against vesicants.
Collapse
Affiliation(s)
- Irene M Wohlman
- Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States
| | - Gabriella M Composto
- Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States
| | - Diane E Heck
- Environmental Health Science, New York Medical College, Valhalla, NY, United States
| | - Ned D Heindel
- Department of Chemistry, Lehigh University, Bethlehem, PA, United States
| | - C Jeffrey Lacey
- Department of Chemistry, Lehigh University, Bethlehem, PA, United States
| | | | | | | | - Donald R Gerecke
- Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States
| | - Debra L Laskin
- Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States
| | - Laurie B Joseph
- Department of Pharmacology and Toxicology, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ, United States
| | - Jeffrey D Laskin
- Environmental and Occupational Health, Rutgers University School of Public Health, Piscataway, NJ, United States.
| |
Collapse
|
57
|
Abdel-Salam O. Gastric acid inhibitory and gastric protective effects of Cannabis and cannabinoids. ASIAN PAC J TROP MED 2016; 9:413-9. [PMID: 27261847 DOI: 10.1016/j.apjtm.2016.04.021] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2016] [Revised: 02/16/2016] [Accepted: 03/10/2016] [Indexed: 11/26/2022] Open
Abstract
Cannabis sativa has long been known for its psychotropic effect. Only recently with the discovery of the cannabinoid receptors, their endogenous legends and the enzymes responsible for their synthesis and degradation, the role of this 'endocannabinoid system' in different pathophysiologic processes is beginning to be delineated. There is evidence that CB1 receptor stimulation with synthetic cannabinoids or Cannabis sativa extracts rich in Δ(9)-tetrahydrocannabinol inhibit gastric acid secretion in humans and experimental animals. This is specially seen when gastric acid secretion is stimulated by pentagastrin, carbachol or 2-deoxy-d-glucose. Cannabis and/or cannabinoids protect the gastric mucosa against noxious challenge with non-steroidal anti-inflammatory drugs, ethanol as well as against stress-induced mucosal damage. Cannabis/cannabinoids might protect the gastric mucosa by virtue of its antisecretory, antioxidant, anti-inflammatory, and vasodilator properties.
Collapse
Affiliation(s)
- Omar Abdel-Salam
- Department of Toxicology and Narcotics, Medical Division, National Research Centre, Tahrir Street, Dokki, Cairo, Egypt.
| |
Collapse
|
58
|
Brindisi M, Maramai S, Gemma S, Brogi S, Grillo A, Di Cesare Mannelli L, Gabellieri E, Lamponi S, Saponara S, Gorelli B, Tedesco D, Bonfiglio T, Landry C, Jung KM, Armirotti A, Luongo L, Ligresti A, Piscitelli F, Bertucci C, Dehouck MP, Campiani G, Maione S, Ghelardini C, Pittaluga A, Piomelli D, Di Marzo V, Butini S. Development and Pharmacological Characterization of Selective Blockers of 2-Arachidonoyl Glycerol Degradation with Efficacy in Rodent Models of Multiple Sclerosis and Pain. J Med Chem 2016; 59:2612-32. [PMID: 26888301 DOI: 10.1021/acs.jmedchem.5b01812] [Citation(s) in RCA: 62] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022]
Abstract
We report the discovery of compound 4a, a potent β-lactam-based monoacylglycerol lipase (MGL) inhibitor characterized by an irreversible and stereoselective mechanism of action, high membrane permeability, high brain penetration evaluated using a human in vitro blood-brain barrier model, high selectivity in binding and affinity-based proteomic profiling assays, and low in vitro toxicity. Mode-of-action studies demonstrate that 4a, by blocking MGL, increases 2-arachidonoylglycerol and behaves as a cannabinoid (CB1/CB2) receptor indirect agonist. Administration of 4a in mice suffering from experimental autoimmune encephalitis ameliorates the severity of the clinical symptoms in a CB1/CB2-dependent manner. Moreover, 4a produced analgesic effects in a rodent model of acute inflammatory pain, which was antagonized by CB1 and CB2 receptor antagonists/inverse agonists. 4a also relieves the neuropathic hypersensitivity induced by oxaliplatin. Given these evidence, 4a, as MGL selective inhibitor, could represent a valuable lead for the future development of therapeutic options for multiple sclerosis and chronic pain.
Collapse
Affiliation(s)
- Margherita Brindisi
- European Research Centre for Drug Discovery and Development (NatSynDrugs), University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| | - Samuele Maramai
- European Research Centre for Drug Discovery and Development (NatSynDrugs), University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| | - Sandra Gemma
- European Research Centre for Drug Discovery and Development (NatSynDrugs), University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| | - Simone Brogi
- European Research Centre for Drug Discovery and Development (NatSynDrugs), University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| | - Alessandro Grillo
- European Research Centre for Drug Discovery and Development (NatSynDrugs), University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| | - Lorenzo Di Cesare Mannelli
- Department of Neuroscience, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Firenze , V.le G. Pieraccini 6, 50139 Firenze, Italy
| | - Emanuele Gabellieri
- European Research Centre for Drug Discovery and Development (NatSynDrugs), University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| | - Stefania Lamponi
- European Research Centre for Drug Discovery and Development (NatSynDrugs), University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| | - Simona Saponara
- Department of Life Sciences, University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| | - Beatrice Gorelli
- Department of Life Sciences, University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| | - Daniele Tedesco
- Department of Pharmacy and Biotechnology Alma Mater Studiorum, University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy
| | - Tommaso Bonfiglio
- Department of Pharmacy, Section of Pharmacology and Toxicology, University of Genova , Viale Cembrano 4, Genova, 16148, Italy
| | - Christophe Landry
- Laboratoire de la Barrière Hémato-Encéphalique (LBHE), University of Artois , EA 2465, F62300 Lens, France
| | - Kwang-Mook Jung
- Department of Anatomy and Neurobiology, University of California , Irvine, California 92617, United States
| | - Andrea Armirotti
- Drug Discovery and Development, Istituto Italiano di Tecnologia , 16163 Genova, Italy
| | - Livio Luongo
- Endocannabinoid Research Group, Department of Experimental Medicine, Division of Pharmacology "L. Donatelli", Second University of Napoli , 80138 Napoli, Italy
| | - Alessia Ligresti
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, CNR , 80078 Pozzuoli (Napoli), Italy
| | - Fabiana Piscitelli
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, CNR , 80078 Pozzuoli (Napoli), Italy
| | - Carlo Bertucci
- Department of Pharmacy and Biotechnology Alma Mater Studiorum, University of Bologna , Via Belmeloro 6, 40126 Bologna, Italy
| | - Marie-Pierre Dehouck
- Laboratoire de la Barrière Hémato-Encéphalique (LBHE), University of Artois , EA 2465, F62300 Lens, France
| | - Giuseppe Campiani
- European Research Centre for Drug Discovery and Development (NatSynDrugs), University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| | - Sabatino Maione
- Endocannabinoid Research Group, Department of Experimental Medicine, Division of Pharmacology "L. Donatelli", Second University of Napoli , 80138 Napoli, Italy
| | - Carla Ghelardini
- Department of Neuroscience, Psychology, Drug Research and Child Health, Section of Pharmacology and Toxicology, University of Firenze , V.le G. Pieraccini 6, 50139 Firenze, Italy
| | - Anna Pittaluga
- Department of Pharmacy, Section of Pharmacology and Toxicology, University of Genova , Viale Cembrano 4, Genova, 16148, Italy.,Center of Excellence for Biomedical Research, University of Genova , Viale Benedetto XV, 16132 Genova, Italy
| | - Daniele Piomelli
- Department of Anatomy and Neurobiology, University of California , Irvine, California 92617, United States
| | - Vincenzo Di Marzo
- Endocannabinoid Research Group, Institute of Biomolecular Chemistry, CNR , 80078 Pozzuoli (Napoli), Italy
| | - Stefania Butini
- European Research Centre for Drug Discovery and Development (NatSynDrugs), University of Siena , via Aldo Moro 2, I-53100 Siena, Italy
| |
Collapse
|
59
|
Ghrelin and endocannabinoids participation in morphine-induced effects in the rat nucleus accumbens. Psychopharmacology (Berl) 2016; 233:469-84. [PMID: 26507196 DOI: 10.1007/s00213-015-4119-3] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/18/2015] [Accepted: 10/15/2015] [Indexed: 12/11/2022]
Abstract
RATIONALE AND OBJECTIVES In addition to dopamine, endocannabinoids are thought to participate in neural reward mechanisms of opioids. Number of recent studies suggests crucial involvement of ghrelin in some addictive drugs effects. Our previous results showed that ghrelin participates in morphine-induced changes in the mesolimbic dopaminergic system associated with reward processing. The goal of the present study was to test whether the growth hormone secretagogue receptor (GHS-R1A) antagonist JMV2959 was able to influence morphine-induced effects on anandamide (N-arachidonoylethanolamine, AEA) and 2-arachidonoylglycerol (2-AG) in the nucleus accumbens shell (NACSh). METHODS We used in vivo microdialysis to determine changes in levels of AEA and 2-AG in the NACSh in rats following (i) an acute morphine dose (5, 10 mg/kg s.c.) with and without JMV2959 pretreatment (3, 6 mg/kg i.p.) or (ii) a morphine challenge dose (5 mg/kg s.c.) with and without JMV2959 (3, 6 mg/kg i.p.) pretreatment, administered during abstinence following repeated doses of morphine (5 days, 10-40 mg/kg). Co-administration of ghrelin (40 ug/kg i.p.) was used to verify the ghrelin mechanisms involvement. RESULTS Pretreatment with JMV2959 significantly and dose-dependently reversed morphine-induced anandamide increases in the NACSh in both the acute and longer-term models, resulting in a significant AEA decrease. JMV2959 significantly intensified acute morphine-induced decreases in accumbens 2-AG levels and attenuated morphine challenge-induced 2-AG decreases. JMV2959 pretreatment significantly reduced concurrent morphine challenge-induced behavioral sensitization. JMV2959 pretreatment effects were abolished by co-administration of ghrelin. CONCLUSIONS Our results indicate significant involvement of ghrelin signaling in morphine-induced endocannabinoid changes in the NACSh.
Collapse
|
60
|
Cairns EA, Baldridge WH, Kelly MEM. The Endocannabinoid System as a Therapeutic Target in Glaucoma. Neural Plast 2016; 2016:9364091. [PMID: 26881140 PMCID: PMC4737462 DOI: 10.1155/2016/9364091] [Citation(s) in RCA: 44] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2015] [Accepted: 11/10/2015] [Indexed: 11/17/2022] Open
Abstract
Glaucoma is an irreversible blinding eye disease which produces progressive retinal ganglion cell (RGC) loss. Intraocular pressure (IOP) is currently the only modifiable risk factor, and lowering IOP results in reduced risk of progression of the disorder. The endocannabinoid system (ECS) has attracted considerable attention as a potential target for the treatment of glaucoma, largely due to the observed IOP lowering effects seen after administration of exogenous cannabinoids. However, recent evidence has suggested that modulation of the ECS may also be neuroprotective. This paper will review the use of cannabinoids in glaucoma, presenting pertinent information regarding the pathophysiology of glaucoma and how alterations in cannabinoid signalling may contribute to glaucoma pathology. Additionally, the mechanisms and potential for the use of cannabinoids and other novel agents that target the endocannabinoid system in the treatment of glaucoma will be discussed.
Collapse
Affiliation(s)
- Elizabeth A. Cairns
- Department of Pharmacology, Dalhousie University, Halifax, NS, Canada B3H 4R2
| | - William H. Baldridge
- Department of Medical Neuroscience, Dalhousie University, Halifax, NS, Canada B3H 4R2
- Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada B3H 4R2
| | - Melanie E. M. Kelly
- Department of Pharmacology, Dalhousie University, Halifax, NS, Canada B3H 4R2
- Department of Ophthalmology and Visual Sciences, Dalhousie University, Halifax, NS, Canada B3H 4R2
| |
Collapse
|
61
|
Zettl UK, Rommer P, Hipp P, Patejdl R. Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis. Ther Adv Neurol Disord 2016; 9:9-30. [PMID: 26788128 PMCID: PMC4710104 DOI: 10.1177/1756285615612659] [Citation(s) in RCA: 43] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Spasticity, one of the main symptoms of multiple sclerosis (MS), can affect more than 80% of MS patients during the course of their disease and is often not treated adequately. δ-9-Tetrahydrocannabinol-cannabidiol (THC-CBD) oromucosal spray is a plant-derived, standardized cannabinoid-based oromucosal spray medicine for add-on treatment of moderate to severe, resistant multiple sclerosis-induced spasticity. This article reviews the current evidence for the efficacy and safety, with dizziness and fatigue as the most common treatment-related adverse events, being mostly mild to moderate in severity. Results from both randomized controlled phase III studies involving about,1600 MS patients or 1500 patient-years and recently published studies on everyday clinical practice involving more than 1000 patients or more than,1000 patient-years are presented.
Collapse
Affiliation(s)
- Uwe K. Zettl
- Department of Neurology, University of Rostock, Gehlsheimer Straße 20, D-18147 Rostock, Germany
| | - Paulus Rommer
- Department of Neurology, University of Rostock, Germany
- Department of Neurology, Medical University of Vienna, Austria
| | | | - Robert Patejdl
- Department of Neurology, University of Rostock, Germany Oscar-Langendorff-Institute of Physiology, University of Rostock, Germany
| |
Collapse
|
62
|
Brindisi M, Brogi S, Maramai S, Grillo A, Borrelli G, Butini S, Novellino E, Allarà M, Ligresti A, Campiani G, Di Marzo V, Gemma S. Harnessing the pyrroloquinoxaline scaffold for FAAH and MAGL interaction: definition of the structural determinants for enzyme inhibition. RSC Adv 2016. [DOI: 10.1039/c6ra12524g] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022] Open
Abstract
The pharmacogenic pyrroloquinoxaline scaffold has been exploited for developing piperazine and 4-aminopiperidine carboxamides/carbamates as inhibitors of the endocannabinoids’ catabolic enzymes fatty acid amide hydrolase and monoacylglycerol lipase.
Collapse
|
63
|
The Effects of the Endocannabinoids Anandamide and 2-Arachidonoylglycerol on Human Osteoblast Proliferation and Differentiation. PLoS One 2015; 10:e0136546. [PMID: 26414859 PMCID: PMC4587563 DOI: 10.1371/journal.pone.0136546] [Citation(s) in RCA: 19] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2015] [Accepted: 08/05/2015] [Indexed: 12/15/2022] Open
Abstract
The endocannabinoid system is expressed in bone, although its role in the regulation of bone growth is controversial. Many studies have examined the effect of endocannabinoids directly on osteoclast function, but few have examined their role in human osteoblast function, which was the aim of the present study. Human osteoblasts were treated from seeding with increasing concentrations of anandamide or 2-arachidonoylglycerol for between 1 and 21 days. Cell proliferation (DNA content) and differentiation (alkaline phosphatase (ALP), collagen and osteocalcin secretion and calcium deposition) were measured. Anandamide and 2-arachidonoylglycerol significantly decreased osteoblast proliferation after 4 days, associated with a concentration-dependent increase in ALP. Inhibition of endocannabinoid degradation enzymes to increase endocannabinoid tone resulted in similar increases in ALP production. 2-arachidonoylglycerol also decreased osteocalcin secretion. After prolonged (21 day) treatment with 2-arachidonoylglycerol, there was a decrease in collagen content, but no change in calcium deposition. Anandamide did not affect collagen or osteocalcin, but reduced calcium deposition. Anandamide increased levels of phosphorylated CREB, ERK 1/2 and JNK, while 2-arachidonoylglycerol increased phosphorylated CREB and Akt. RT-PCR demonstrated the expression of CB2 and TRPV1, but not CB1 in HOBs. Anandamide-induced changes in HOB differentiation were CB1 and CB2-independent and partially reduced by TRPV1 antagonism, and reduced by inhibition of ERK 1/2 and JNK. Our results have demonstrated a clear involvement of anandamide and 2-arachidonoylglycerol in modulating the activity of human osteoblasts, with anandamide increasing early cell differentiation and 2-AG increasing early, but decreasing late osteoblast-specific markers of differentiation.
Collapse
|
64
|
Wollank Y, Ramer R, Ivanov I, Salamon A, Peters K, Hinz B. Inhibition of FAAH confers increased stem cell migration via PPARα. J Lipid Res 2015; 56:1947-60. [PMID: 26263913 DOI: 10.1194/jlr.m061473] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Indexed: 02/07/2023] Open
Abstract
Regenerative activity in tissues of mesenchymal origin depends on the migratory potential of mesenchymal stem cells (MSCs). The present study focused on inhibitors of the enzyme fatty acid amide hydrolase (FAAH), which catalyzes the degradation of endocannabinoids (anandamide, 2-arachidonoylglycerol) and endocannabinoid-like substances (N-oleoylethanolamine, N-palmitoylethanolamine). Boyden chamber assays, the FAAH inhibitors, URB597 and arachidonoyl serotonin (AA-5HT), were found to increase the migration of human adipose-derived MSCs. LC-MS analyses revealed increased levels of all four aforementioned FAAH substrates in MSCs incubated with either FAAH inhibitor. Following addition to MSCs, all FAAH substrates mimicked the promigratory action of FAAH inhibitors. Promigratory effects of FAAH inhibitors and substrates were causally linked to activation of p42/44 MAPKs, as well as to cytosol-to-nucleus translocation of the transcription factor, PPARα. Whereas PPARα activation by FAAH inhibitors and substrates became reversed upon inhibition of p42/44 MAPK activation, a blockade of PPARα left p42/44 MAPK phosphorylation unaltered. Collectively, these data demonstrate FAAH inhibitors and substrates to cause p42/44 MAPK phosphorylation, which subsequently activates PPARα to confer increased migration of MSCs. This novel pathway may be involved in regenerative effects of endocannabinoids whose degradation could be a target of pharmacological intervention by FAAH inhibitors.
Collapse
Affiliation(s)
- Yvonne Wollank
- Institute of Toxicology and Pharmacology, Rostock University Medical Center, D-18057 Rostock, Germany Department of Cell Biology, Rostock University Medical Center, D-18057 Rostock, Germany
| | - Robert Ramer
- Institute of Toxicology and Pharmacology, Rostock University Medical Center, D-18057 Rostock, Germany
| | - Igor Ivanov
- Institute of Toxicology and Pharmacology, Rostock University Medical Center, D-18057 Rostock, Germany
| | - Achim Salamon
- Department of Cell Biology, Rostock University Medical Center, D-18057 Rostock, Germany
| | - Kirsten Peters
- Department of Cell Biology, Rostock University Medical Center, D-18057 Rostock, Germany
| | - Burkhard Hinz
- Institute of Toxicology and Pharmacology, Rostock University Medical Center, D-18057 Rostock, Germany
| |
Collapse
|
65
|
Navia-Paldanius D, Aaltonen N, Lehtonen M, Savinainen JR, Taschler U, Radner FPW, Zimmermann R, Laitinen JT. Increased tonic cannabinoid CB1R activity and brain region-specific desensitization of CB1R Gi/o signaling axis in mice with global genetic knockout of monoacylglycerol lipase. Eur J Pharm Sci 2015; 77:180-8. [PMID: 26070239 DOI: 10.1016/j.ejps.2015.06.005] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/22/2014] [Revised: 04/16/2015] [Accepted: 06/08/2015] [Indexed: 11/28/2022]
Abstract
In mammalian brain, monoacylglycerol lipase (MAGL) is the primary enzyme responsible for terminating signaling function of the endocannabinoid 2-arachidonoylglycerol (2-AG). Previous in vivo studies with mice indicate that both genetic and chronic pharmacological inactivation of MAGL result in 8-30-fold increase of 2-AG concentration in the brain, causing desensitization and downregulation of cannabinoid CB1 receptor (CB1R) activity, leading to functional and behavioral tolerance. However, direct evidence for reduced CB1R activity in the brain is lacking. In this study, we used functional autoradiography to assess basal and agonist-stimulated CB1R-dependent Gi/o protein activity in multiple brain regions of MAGL-KO mice in comparison to their wild-type (WT) littermates. In addition, the role of endogenous cannabinoids in basal CB1R signaling was assessed after comprehensive pharmacological blockade of 2-AG hydrolysis by determining the contents of endocannabinoids (eCBs) in WT and MAGL-KO brain tissues by LC/MS/MS technology. To show whether lack of MAGL cause compensatory alterations in the serine hydrolase activity, we compared serine hydrolase pattern of WT and MAGL-KO using activity-based protein profiling. Consistent with studies using chronic pharmacological MAGL inactivation in vivo, we observed a statistically significant decrease of CB1R-Gi/o signaling in most of the studied brain regions. In MAGL-KO brain sections, elevated 2-AG levels were mirrored to heightened basal CB1R-dependent Gi/o-activity, as well as, dampened agonist-evoked responses in several brain regions. The non-selective serine hydrolase inhibitor methylarachidonoylfluorophosphonate (MAFP) was able to significantly elevate 2-AG levels in brain sections of MAGL-KO mice, indicating that additional serine hydrolases possess 2-AG hydrolytic activity in MAGL-KO brain sections.
Collapse
Affiliation(s)
- Dina Navia-Paldanius
- School of Medicine, Institute of Biomedicine/Physiology, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland; School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.
| | - Niina Aaltonen
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.
| | - Marko Lehtonen
- School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.
| | - Juha R Savinainen
- School of Medicine, Institute of Biomedicine/Physiology, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.
| | - Ulrike Taschler
- Institute of Molecular Biosciences, Karl Franzens Universität Graz, Heinrichstrasse 31/2, 8010 Graz, Austria.
| | - Franz P W Radner
- Institute of Molecular Biosciences, Karl Franzens Universität Graz, Heinrichstrasse 31/2, 8010 Graz, Austria.
| | - Robert Zimmermann
- Institute of Molecular Biosciences, Karl Franzens Universität Graz, Heinrichstrasse 31/2, 8010 Graz, Austria.
| | - Jarmo T Laitinen
- School of Medicine, Institute of Biomedicine/Physiology, University of Eastern Finland, P.O. Box 1627, 70211 Kuopio, Finland.
| |
Collapse
|
66
|
Hong J, Nandiwada V, Jones V, Lu M, Warner DS, Mukhopadhyay S, Sheng H. CB1 cannabinoid receptor agonist inhibits matrix metalloproteinase activity in spinal cord injury: A possible mechanism of improved recovery. Neurosci Lett 2015; 597:19-24. [DOI: 10.1016/j.neulet.2015.04.016] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2014] [Revised: 02/19/2015] [Accepted: 04/09/2015] [Indexed: 10/23/2022]
|
67
|
Moris D, Georgopoulos S, Felekouras E, Patsouris E, Theocharis S. The effect of endocannabinoid system in ischemia-reperfusion injury: a friend or a foe? Expert Opin Ther Targets 2015; 19:1261-75. [PMID: 25936364 DOI: 10.1517/14728222.2015.1043268] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
INTRODUCTION In recent years, the endocannabinoid system has emerged as a new therapeutic target in variety of disorders associated with inflammation and tissue injury, including those of the neuronal, liver, renal and cardiovascular system. The aim of the present review is to elucidate the effect of endocannabinoid system on ischemia reperfusion injury (IRI) in different organs and systems. AREAS COVERED The MEDLINE/PubMed database was searched for publications with the medical subject heading Cannabinoids* (CBs), CB receptors*, organ*, ischemia/reperfusion injury*, endocannabinoid* and system*. The initial relevant studies retrieved from the literature were 91 from PubMed. This number was initially limited to 35, after excluding the reviews and studies reporting data for receptors other than cannabinoid. EXPERT OPINION CB2 receptors may play an important compensatory role in controlling tissue inflammation and injury in cells of the neuronal, cardiovascular, liver and renal systems, as well as in infiltrating monocytes/macrophages and leukocytes during various pathological conditions of the systems (atherosclerosis, restenosis, stroke, myocardial infarction, heart, liver and renal failure). These receptors limit inflammation and associated tissue injury. On the basis of preclinical results, pharmacological modulation of CB2 receptors may hold a unique therapeutic potential in stroke, myocardial infarction, atherosclerosis, IRI and liver disease.
Collapse
Affiliation(s)
- Demetrios Moris
- National and Kapodistrian University of Athens , Anastasiou Gennadiou 56, 11474, Athens , Greece +30 210 6440590 ;
| | | | | | | | | |
Collapse
|
68
|
Consequences of early life stress on the expression of endocannabinoid-related genes in the rat brain. Behav Pharmacol 2015; 25:547-56. [PMID: 25083571 DOI: 10.1097/fbp.0000000000000068] [Citation(s) in RCA: 58] [Impact Index Per Article: 6.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
The endocannabinoid system is involved in several physiological and pathological states including anxiety, depression, addiction and other neuropsychiatric disorders. Evidence from human and rodent studies suggests that exposure to early life stress may increase the risk of psychopathology later in life. Indeed, maternal deprivation (MD) (24 h at postnatal day 9) in rats induces behavioural alterations associated with depressive-like and psychotic-like symptoms, as well as important changes in the endocannabinoid system. As most neuropsychiatric disorders first appear at adolescence, and show remarkable sexual dimorphisms in their prevalence and severity, in the present study, we analysed the gene expression of the main components of the brain cannabinoid system in adolescent (postnatal day 46) Wistar male and female rats reared under standard conditions or exposed to MD. For this, we analysed, by real-time quantitative PCR, the expression of genes encoding for CB1 and CB2 receptors, TRPV1 and GPR55 (Cnr1, Cnr2a, Cnr2b, Trpv1, and Gpr55), for the major enzymes of synthesis, N-acyl phosphatidyl-ethanolamine phospholipase D (NAPE-PLD) and diacylglycerol lipase (DAGL) (Nape-pld, Dagla and Daglb), and degradation, fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) (Faah, Magl and Cox-2), in specific brain regions, that is, the frontal cortex, ventral and dorsal striatum, dorsal hippocampus and amygdala. In males, MD increased the genetic expression of all the genes studied within the frontal cortex, whereas in females such an increase was observed only in the hippocampus. In conclusion, the endocannabinoid system is sensitive to early life stress at the gene expression level in a sex-dependent and region-dependent manner, and these changes are already evident in the adolescent brain.
Collapse
|
69
|
Patsenker E, Sachse P, Chicca A, Gachet MS, Schneider V, Mattsson J, Lanz C, Worni M, de Gottardi A, Semmo M, Hampe J, Schafmayer C, Brenneisen R, Gertsch J, Stickel F, Semmo N. Elevated levels of endocannabinoids in chronic hepatitis C may modulate cellular immune response and hepatic stellate cell activation. Int J Mol Sci 2015; 16:7057-76. [PMID: 25826533 PMCID: PMC4425004 DOI: 10.3390/ijms16047057] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2015] [Revised: 03/06/2015] [Accepted: 03/23/2015] [Indexed: 12/17/2022] Open
Abstract
The endocannabinoid (EC) system is implicated in many chronic liver diseases, including hepatitis C viral (HCV) infection. Cannabis consumption is associated with fibrosis progression in patients with chronic hepatitis C (CHC), however, the role of ECs in the development of CHC has never been explored. To study this question, anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) were quantified in samples of HCV patients and healthy controls by gas and liquid chromatography mass spectrometry. Fatty acid amide hydrolase (FAAH) and monoaclyglycerol lipase (MAGL) activity was assessed by [3H]AEA and [3H]2-AG hydrolysis, respectively. Gene expression and cytokine release were assayed by TaqMan PCR and ELISpot, respectively. AEA and 2-AG levels were increased in plasma of HCV patients, but not in liver tissues. Hepatic FAAH and MAGL activity was not changed. In peripheral blood mononuclear cells (PBMC), ECs inhibited IFN-γ, TNF-α, and IL-2 secretion. Inhibition of IL-2 by endogenous AEA was stronger in PBMC from HCV patients. In hepatocytes, 2-AG induced the expression of IL-6, -17A, -32 and COX-2, and enhanced activation of hepatic stellate cells (HSC) co-cultivated with PBMC from subjects with CHC. In conclusion, ECs are increased in plasma of patients with CHC and might reveal immunosuppressive and profibrogenic effects.
Collapse
Affiliation(s)
- Eleonora Patsenker
- Department of Clinical Research, University of Bern, Bern 3010, Switzerland.
| | - Philip Sachse
- Department of Clinical Research, University of Bern, Bern 3010, Switzerland.
| | - Andrea Chicca
- Institute of Biochemistry and Molecular Medicine, University of Bern, Bern 3012, Switzerland.
| | - María Salomé Gachet
- Institute of Biochemistry and Molecular Medicine, University of Bern, Bern 3012, Switzerland.
| | - Vreni Schneider
- Department of Clinical Research, University of Bern, Bern 3010, Switzerland.
| | - Johan Mattsson
- Department of Clinical Research, Laboratory of Phytopharmacology, Bioanalytics and Pharmacokinetics, University of Bern, Bern 3010, Switzerland.
| | - Christian Lanz
- Department of Clinical Research, Laboratory of Phytopharmacology, Bioanalytics and Pharmacokinetics, University of Bern, Bern 3010, Switzerland.
| | - Mathias Worni
- Department of Visceral Surgery and Medicine, Inselspital, University of Bern, Bern 3010, Switzerland.
| | - Andrea de Gottardi
- Department of Visceral Surgery and Medicine, Inselspital, University of Bern, Bern 3010, Switzerland.
| | - Mariam Semmo
- Department of Nephrology, Inselspital, University of Bern, Bern 3010, Switzerland.
| | - Jochen Hampe
- Department of Medicine II, Division of Gastroenterology, University of Dresden, Dresden 01307, Germany.
| | - Clemens Schafmayer
- Department of Visceral Surgery, University of Schleswig-Holstein, Campus Kiel, Kiel 24105, Germany.
| | - Rudolf Brenneisen
- Department of Clinical Research, Laboratory of Phytopharmacology, Bioanalytics and Pharmacokinetics, University of Bern, Bern 3010, Switzerland.
| | - Jürg Gertsch
- Institute of Biochemistry and Molecular Medicine, University of Bern, Bern 3012, Switzerland.
| | - Felix Stickel
- Department of Clinical Research, University of Bern, Bern 3010, Switzerland.
| | - Nasser Semmo
- Department of Clinical Research, University of Bern, Bern 3010, Switzerland.
- Department of Visceral Surgery and Medicine, Inselspital, University of Bern, Bern 3010, Switzerland.
| |
Collapse
|
70
|
Lisboa SF, Gomes FV, Silva AL, Uliana DL, Camargo LHA, Guimarães FS, Cunha FQ, Joca SRL, Resstel LBM. Increased Contextual Fear Conditioning in iNOS Knockout Mice: Additional Evidence for the Involvement of Nitric Oxide in Stress-Related Disorders and Contribution of the Endocannabinoid System. Int J Neuropsychopharmacol 2015; 18:pyv005. [PMID: 25618404 PMCID: PMC4571624 DOI: 10.1093/ijnp/pyv005] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/03/2014] [Accepted: 01/12/2015] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Inducible or neuronal nitric oxide synthase gene deletion increases or decreases anxiety-like behavior in mice, respectively. Since nitric oxide and endocannabinoids interact to modulate defensive behavior, the former effect could involve a compensatory increase in basal brain nitric oxide synthase activity and/or changes in the endocannabinoid system. Thus, we investigated the expression and extinction of contextual fear conditioning of inducible nitric oxide knockout mice and possible involvement of endocannabinoids in these responses. METHODS We evaluated the effects of a preferential neuronal nitric oxide synthase inhibitor, 7-nitroindazol, nitric oxide synthase activity, and mRNA changes of nitrergic and endocannabinoid systems components in the medial prefrontal cortex and hippocampus of wild-type and knockout mice. The effects of URB597, an inhibitor of the fatty acid amide hydrolase enzyme, which metabolizes the endocannabinoid anandamide, WIN55,212-2, a nonselective cannabinoid agonist, and AM281, a selective CB1 antagonist, on contextual fear conditioning were also evaluated. RESULTS Contextual fear conditioning expression was similar in wild-type and knockout mice, but the latter presented extinction deficits and increased basal nitric oxide synthase activity in the medial prefrontal cortex. 7-Nitroindazol decreased fear expression and facilitated extinction in wild-type and knockout mice. URB597 decreased fear expression in wild-type and facilitated extinction in knockout mice, whereas WIN55,212-2 and AM281 increased it in wild-type mice. Nonconditioned knockout mice showed changes in the mRNA expression of nitrergic and endocannabinoid system components in the medial prefrontal cortex and hippocampus that were modified by fear conditioning. CONCLUSION These data reinforce the involvement of the nitric oxide and endocannabinoids (anandamide) in stress-related disorders and point to a deregulation of the endocannabinoid system in situations where nitric oxide signaling is increased.
Collapse
MESH Headings
- Animals
- Arachidonic Acids/metabolism
- Benzamides/pharmacology
- Benzoxazines/pharmacology
- Cannabinoid Receptor Agonists/pharmacology
- Cannabinoid Receptor Antagonists/pharmacology
- Carbamates/pharmacology
- Conditioning, Psychological/drug effects
- Conditioning, Psychological/physiology
- Endocannabinoids/metabolism
- Enzyme Inhibitors/pharmacology
- Extinction, Psychological/drug effects
- Extinction, Psychological/physiology
- Fear/drug effects
- Fear/physiology
- Freezing Reaction, Cataleptic/drug effects
- Freezing Reaction, Cataleptic/physiology
- Hippocampus/drug effects
- Hippocampus/metabolism
- Indazoles/pharmacology
- Male
- Mice, Inbred C57BL
- Mice, Knockout
- Morpholines/pharmacology
- Naphthalenes/pharmacology
- Nitric Oxide/metabolism
- Nitric Oxide Synthase Type II/antagonists & inhibitors
- Nitric Oxide Synthase Type II/genetics
- Nitric Oxide Synthase Type II/metabolism
- Polyunsaturated Alkamides/metabolism
- Prefrontal Cortex/drug effects
- Prefrontal Cortex/metabolism
- Pyrazoles/pharmacology
- RNA, Messenger/metabolism
- Receptor, Cannabinoid, CB1/antagonists & inhibitors
- Receptor, Cannabinoid, CB1/metabolism
- Stress, Psychological/metabolism
Collapse
Affiliation(s)
- Sabrina F Lisboa
- Department of Pharmacology, Medical School of Ribeirão Preto (Drs Lisboa, Gomes, Silva, Cunha, and Resstel, Ms Uliana and Ms Camargo), Department of Pharmacology, School of Pharmaceutical Sciences of Ribeirão Preto (Dr Joca), and Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Lisboa, Gomes, Guimarães, Joca, and Resstel).
| | - Felipe V Gomes
- Department of Pharmacology, Medical School of Ribeirão Preto (Drs Lisboa, Gomes, Silva, Cunha, and Resstel, Ms Uliana and Ms Camargo), Department of Pharmacology, School of Pharmaceutical Sciences of Ribeirão Preto (Dr Joca), and Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Lisboa, Gomes, Guimarães, Joca, and Resstel)
| | - Andréia L Silva
- Department of Pharmacology, Medical School of Ribeirão Preto (Drs Lisboa, Gomes, Silva, Cunha, and Resstel, Ms Uliana and Ms Camargo), Department of Pharmacology, School of Pharmaceutical Sciences of Ribeirão Preto (Dr Joca), and Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Lisboa, Gomes, Guimarães, Joca, and Resstel)
| | - Daniela L Uliana
- Department of Pharmacology, Medical School of Ribeirão Preto (Drs Lisboa, Gomes, Silva, Cunha, and Resstel, Ms Uliana and Ms Camargo), Department of Pharmacology, School of Pharmaceutical Sciences of Ribeirão Preto (Dr Joca), and Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Lisboa, Gomes, Guimarães, Joca, and Resstel)
| | - Laura H A Camargo
- Department of Pharmacology, Medical School of Ribeirão Preto (Drs Lisboa, Gomes, Silva, Cunha, and Resstel, Ms Uliana and Ms Camargo), Department of Pharmacology, School of Pharmaceutical Sciences of Ribeirão Preto (Dr Joca), and Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Lisboa, Gomes, Guimarães, Joca, and Resstel)
| | - Francisco S Guimarães
- Department of Pharmacology, Medical School of Ribeirão Preto (Drs Lisboa, Gomes, Silva, Cunha, and Resstel, Ms Uliana and Ms Camargo), Department of Pharmacology, School of Pharmaceutical Sciences of Ribeirão Preto (Dr Joca), and Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Lisboa, Gomes, Guimarães, Joca, and Resstel)
| | - Fernando Q Cunha
- Department of Pharmacology, Medical School of Ribeirão Preto (Drs Lisboa, Gomes, Silva, Cunha, and Resstel, Ms Uliana and Ms Camargo), Department of Pharmacology, School of Pharmaceutical Sciences of Ribeirão Preto (Dr Joca), and Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Lisboa, Gomes, Guimarães, Joca, and Resstel)
| | - Sâmia R L Joca
- Department of Pharmacology, Medical School of Ribeirão Preto (Drs Lisboa, Gomes, Silva, Cunha, and Resstel, Ms Uliana and Ms Camargo), Department of Pharmacology, School of Pharmaceutical Sciences of Ribeirão Preto (Dr Joca), and Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Lisboa, Gomes, Guimarães, Joca, and Resstel)
| | - Leonardo B M Resstel
- Department of Pharmacology, Medical School of Ribeirão Preto (Drs Lisboa, Gomes, Silva, Cunha, and Resstel, Ms Uliana and Ms Camargo), Department of Pharmacology, School of Pharmaceutical Sciences of Ribeirão Preto (Dr Joca), and Center for Interdisciplinary Research on Applied Neurosciences, University of São Paulo, Brazil (Drs Lisboa, Gomes, Guimarães, Joca, and Resstel)
| |
Collapse
|
71
|
Martínez-Martínez E, Gómez I, Martín P, Sánchez A, Román L, Tejerina E, Bonilla F, Merino AG, de Herreros AG, Provencio M, García JM. Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. Oncoscience 2015; 2:131-41. [PMID: 25859556 PMCID: PMC4381706 DOI: 10.18632/oncoscience.119] [Citation(s) in RCA: 47] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2014] [Accepted: 02/06/2015] [Indexed: 12/28/2022] Open
Abstract
Many studies have demonstrated that the endocannabinoid system (ECS) is altered in different tumor types, including colon cancer. However, little is known about the role of the ECS in tumor progression. Here we report the correlation between CB2 expression and pathological data in a series of 175 colorectal cancer patients, as well as the response of the HT29 colon cancer-derived cell line upon CB2 activation. CB2 mRNA was detected in 28.6% of samples tested. It was more frequent in N+ patients and predicts disease free survival and overall survival in colon cancer. In positive samples, CB2 was expressed with great intensity in tumor epithelial cells and correlated with tumor growth. Treatment of HT29 with CB2 agonist revealed membrane loss of E-cadherin and SNAIL1 overexpression. A direct correlation between CB2 and SNAIL1 expression was also found in human tumors. CB2 receptor expression is a poor prognostic marker for colon cancer and the activation of this receptor, with non-apoptotic doses of agonists, could be collaborating with disease progression. These results raise the question whether the activation of CB2 should be considered as anti-tumoral therapy.
Collapse
Affiliation(s)
| | - Irene Gómez
- Department of Medical Oncology, IIS Puerta de Hierro-Majadahonda, Madrid
| | - Paloma Martín
- Department of Pathology, IIS Puerta de Hierro-Majadahonda, Madrid
| | - Antonio Sánchez
- Department of Neuroimmunology, IIS Puerta de Hierro-Majadahonda, Madrid
| | - Laura Román
- Department of Neuroimmunology, IIS Puerta de Hierro-Majadahonda, Madrid
| | - Eva Tejerina
- Department of Pathology, IIS Puerta de Hierro-Majadahonda, Madrid
| | - Félix Bonilla
- Department of Medical Oncology, IIS Puerta de Hierro-Majadahonda, Madrid
| | | | | | - Mariano Provencio
- Department of Medical Oncology, IIS Puerta de Hierro-Majadahonda, Madrid
| | - Jose M García
- Department of Medical Oncology, IIS Puerta de Hierro-Majadahonda, Madrid
| |
Collapse
|
72
|
Griebel G, Pichat P, Beeské S, Leroy T, Redon N, Jacquet A, Françon D, Bert L, Even L, Lopez-Grancha M, Tolstykh T, Sun F, Yu Q, Brittain S, Arlt H, He T, Zhang B, Wiederschain D, Bertrand T, Houtmann J, Rak A, Vallée F, Michot N, Augé F, Menet V, Bergis OE, George P, Avenet P, Mikol V, Didier M, Escoubet J. Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodents. Sci Rep 2015; 5:7642. [PMID: 25560837 PMCID: PMC4284516 DOI: 10.1038/srep07642] [Citation(s) in RCA: 88] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/22/2014] [Accepted: 12/03/2014] [Indexed: 12/27/2022] Open
Abstract
Monoacylglycerol lipase (MAGL) represents a primary degradation enzyme of the endogenous cannabinoid (eCB), 2-arachidonoyglycerol (2-AG). This study reports a potent covalent MAGL inhibitor, SAR127303. The compound behaves as a selective and competitive inhibitor of mouse and human MAGL, which potently elevates hippocampal levels of 2-AG in mice. In vivo, SAR127303 produces antinociceptive effects in assays of inflammatory and visceral pain. In addition, the drug alters learning performance in several assays related to episodic, working and spatial memory. Moreover, long term potentiation (LTP) of CA1 synaptic transmission and acetylcholine release in the hippocampus, two hallmarks of memory function, are both decreased by SAR127303. Although inactive in acute seizure tests, repeated administration of SAR127303 delays the acquisition and decreases kindled seizures in mice, indicating that the drug slows down epileptogenesis, a finding deserving further investigation to evaluate the potential of MAGL inhibitors as antiepileptics. However, the observation that 2-AG hydrolysis blockade alters learning and memory performance, suggests that such drugs may have limited value as therapeutic agents.
Collapse
Affiliation(s)
- Guy Griebel
- Sanofi R&D, Exploratory Unit, Chilly-Mazarin, France
| | | | - Sandra Beeské
- Sanofi R&D, Exploratory Unit, Chilly-Mazarin, France
| | - Thibaud Leroy
- Sanofi R&D, Exploratory Unit, Chilly-Mazarin, France
| | - Nicolas Redon
- Sanofi R&D, Exploratory Unit, Chilly-Mazarin, France
| | - Agnès Jacquet
- Sanofi R&D, Exploratory Unit, Chilly-Mazarin, France
| | | | | | - Luc Even
- Sanofi R&D, Exploratory Unit, Chilly-Mazarin, France
| | | | | | | | - Qunyan Yu
- Global Oncology Division, Cambridge, USA
| | | | - Heike Arlt
- Global Oncology Division, Cambridge, USA
| | - Timothy He
- Global Oncology Division, Cambridge, USA
| | | | | | - Thomas Bertrand
- Lead Generation To Candidate Realization, Vitry-sur-Seine, France
| | - Jacques Houtmann
- Lead Generation To Candidate Realization, Vitry-sur-Seine, France
| | - Alexey Rak
- Lead Generation To Candidate Realization, Vitry-sur-Seine, France
| | - François Vallée
- Lead Generation To Candidate Realization, Vitry-sur-Seine, France
| | - Nadine Michot
- Lead Generation To Candidate Realization, Vitry-sur-Seine, France
| | - Franck Augé
- Sanofi R&D, Exploratory Unit, Chilly-Mazarin, France
| | | | | | - Pascal George
- Therapeutic Strategic Unit Aging, Chilly-Mazarin, France
| | | | - Vincent Mikol
- Lead Generation To Candidate Realization, Vitry-sur-Seine, France
| | | | | |
Collapse
|
73
|
Kim J, Li Y. Chronic activation of CB2 cannabinoid receptors in the hippocampus increases excitatory synaptic transmission. J Physiol 2015; 593:871-86. [PMID: 25504573 DOI: 10.1113/jphysiol.2014.286633] [Citation(s) in RCA: 74] [Impact Index Per Article: 8.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/31/2014] [Accepted: 12/02/2014] [Indexed: 12/20/2022] Open
Abstract
KEY POINTS The effects of cannabinoids are primarily mediated by two types of cannabinoid receptors, CB1 receptors in the nervous system and CB2 receptors in the immune system. Recent evidence indicates that CB2 receptors are also widely expressed in the brain and involved in neuropsychiatric functions, such as schizophrenia-like behaviours, anxiety, memory, vomiting and pain. The cellular mechanisms by which CB2 receptors regulate neuronal functions are unknown. We show that chronic activation of CB2 receptors in the hippocampus for 7-10 days increases excitatory synaptic transmission, whereas short-term activation of CB2 receptors has little effect on synaptic activity. This study reveals a novel role of CB2 receptors in the brain, which is clearly distinct from that of CB1 receptors, and thus, will help us to understand better the diverse effects of cannabinoids in the nervous system. ABSTRACT The roles of CB1 cannabinoid receptors in regulating neuronal activity have been extensively characterized. Although early studies show that CB1 receptors are present in the nervous system and CB2 cannabinoid receptors are in the immune system, recent evidence indicates that CB2 receptors are also expressed in the brain. Activation or blockade of CB2 receptors in vivo induces neuropsychiatric effects, but the cellular mechanisms of CB2 receptor function are unclear. The aim of this study is to determine how activation of CB2 receptors present in the hippocampus regulates synaptic function. Here, we show that when organotypic cultures of rodent hippocampal slices were treated with a CB2 receptor agonist (JWH133 or GP1a) for 7-10 days, quantal glutamate release became more frequent and spine density was increased via extracellular signal-regulated kinases. Chronic intraperitoneal injection of JWH133 into mice also increased excitatory synaptic transmission. These effects were blocked by a CB2 receptor antagonist (SR144528) or absent from hippocampal slices of CB2 receptor knock-out mice. This study reveals a novel cellular function of CB2 cannabinoid receptors in the hippocampus and provides insights into how cannabinoid receptor subtypes diversify the roles of cannabinoids in the brain.
Collapse
Affiliation(s)
- Jimok Kim
- Department of Neuroscience and Regenerative Medicine, Medical College of Georgia, Georgia Regents University, Augusta, GA, 30912, USA; Department of Neurology, Medical College of Georgia, Georgia Regents University, Augusta, GA, 30912, USA
| | | |
Collapse
|
74
|
Pascual A, Martín-Moreno A, Giusto N, de Ceballos M, Pasquaré S. Normal aging in rats and pathological aging in human Alzheimer’s disease decrease FAAH activity: Modulation by cannabinoid agonists. Exp Gerontol 2014; 60:92-9. [DOI: 10.1016/j.exger.2014.10.011] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2014] [Revised: 10/15/2014] [Accepted: 10/16/2014] [Indexed: 12/21/2022]
|
75
|
Endocannabinoids, related compounds and their metabolic routes. Molecules 2014; 19:17078-106. [PMID: 25347455 PMCID: PMC6271436 DOI: 10.3390/molecules191117078] [Citation(s) in RCA: 119] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2014] [Revised: 10/16/2014] [Accepted: 10/16/2014] [Indexed: 12/27/2022] Open
Abstract
Endocannabinoids are lipid mediators able to bind to and activate cannabinoid receptors, the primary molecular targets responsible for the pharmacological effects of the Δ9-tetrahydrocannabinol. These bioactive lipids belong mainly to two classes of compounds: N-acylethanolamines and acylesters, being N-arachidonoylethanolamine (AEA) and 2-arachidonoylglycerol (2-AG), respectively, their main representatives. During the last twenty years, an ever growing number of fatty acid derivatives (endocannabinoids and endocannabinoid-like compounds) have been discovered and their activities biological is the subject of intense investigations. Here, the most recent advances, from a therapeutic point of view, on endocannabinoids, related compounds, and their metabolic routes will be reviewed.
Collapse
|
76
|
Kohnz RA, Nomura DK. Chemical approaches to therapeutically target the metabolism and signaling of the endocannabinoid 2-AG and eicosanoids. Chem Soc Rev 2014; 43:6859-69. [PMID: 24676249 PMCID: PMC4159426 DOI: 10.1039/c4cs00047a] [Citation(s) in RCA: 66] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
The endocannabinoid system, most popularly known as the target of the psychoactive component of marijuana, Δ(9)-tetrahydrocannabinol (THC), is a signaling network that modulates a diverse range of physiological processes including nociception, behavior, cognitive function, appetite, metabolism, motor control, memory formation, and inflammation. While THC and its derivatives have garnered notoriety in the eyes of the public, the endocannabinoid system consists of two endogenous signaling lipids, 2-arachidonoylglycerol (2-AG) and N-arachidonoylethanolamine (anandamide), which activate cannabinoid receptors CB1 and CB2 in the nervous system and peripheral tissues. This review will focus on the recent efforts to chemically manipulate 2-AG signaling through the development of inhibitors of the 2-AG-synthesizing enzyme diacylglycerol lipase (DAGL) or the 2-AG-degrading enzyme monoacylglycerol lipase (MAGL), and assessing the therapeutic potential of DAGL and MAGL inhibitors in pain, inflammation, degenerative diseases, tissue injury, and cancer.
Collapse
Affiliation(s)
- Rebecca A Kohnz
- Program in Metabolic Biology, University of California, Berkeley, 127 Morgan Hall, Berkeley, CA 94720, USA.
| | | |
Collapse
|
77
|
Structure–affinity relationships and pharmacological characterization of new alkyl-resorcinol cannabinoid receptor ligands: Identification of a dual cannabinoid receptor/TRPA1 channel agonist. Bioorg Med Chem 2014; 22:4770-83. [DOI: 10.1016/j.bmc.2014.07.006] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/07/2014] [Revised: 06/24/2014] [Accepted: 07/02/2014] [Indexed: 11/23/2022]
|
78
|
Messalli EM, Grauso F, Luise R, Angelini A, Rossiello R. Cannabinoid receptor type 1 immunoreactivity and disease severity in human epithelial ovarian tumors. Am J Obstet Gynecol 2014; 211:234.e1-6. [PMID: 24721263 DOI: 10.1016/j.ajog.2014.04.004] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/03/2014] [Revised: 02/24/2014] [Accepted: 04/04/2014] [Indexed: 02/06/2023]
Abstract
OBJECTIVE In light of recent findings indicating that endocannabinoid system has antitumor actions, our study aimed to localize it in the human epithelial ovarian tumors, highlighting the differences among benign, borderline, and invasive forms and correlating cannabinoid receptor type 1 (CB1R) expression with disease severity. STUDY DESIGN We determined CB1R immunohistochemical expression in 66 epithelial ovarian tumors treated in the Department of Woman, Child, and General and Specialized Surgery, Second University of Naples, at S. Maria del Popolo degli Incurabili Hospital (Naples): 36 borderline ovarian tumors, the main target of interest being intermediate forms, 15 benign and 15 invasive ovarian tumors. RESULTS The benign ovarian tumors showed a weak expression of CB1R in the 33% of the cases and moderate expression in the 67% of the cases. Borderline ovarian tumors had a similar trend. They showed weak CB1R expression in 28% of the cases, moderate expression in 53% of the cases, and strong expression in 19% of the cases. In contrast, invasive tumors showed a weak expression of CB1R in 7% of the cases, moderate expression in 20% of the cases, and strong expression in 73% of the cases. CONCLUSION The recorded data show that the expression of CB1R increased from benign and borderline to malignant tumors. In the near future, endocannabinoid receptors might be used in clinical practice, alone or in combination with other markers, to identify or better characterize ovarian tumors, without considering the great opportunity that they might represent as therapeutic targets.
Collapse
Affiliation(s)
- Enrico Michelino Messalli
- Department of Woman, Child, and General and Specialized Surgery, Second University of Naples, Naples, Italy.
| | - Flavio Grauso
- Department of Woman, Child, and General and Specialized Surgery, Second University of Naples, Naples, Italy
| | - Rossella Luise
- Division of Pathology, Department of Public, Clinic, and Preventive Medicine, Second University of Naples, Naples, Italy
| | - Anna Angelini
- Pathologic Service, P.O.S. Maria del Popolo degli Incurabili, Naples, Italy
| | - Raffaele Rossiello
- Division of Pathology, Department of Public, Clinic, and Preventive Medicine, Second University of Naples, Naples, Italy
| |
Collapse
|
79
|
Pucci M, Rapino C, Di Francesco A, Dainese E, D'Addario C, Maccarrone M. Epigenetic control of skin differentiation genes by phytocannabinoids. Br J Pharmacol 2014; 170:581-91. [PMID: 23869687 DOI: 10.1111/bph.12309] [Citation(s) in RCA: 68] [Impact Index Per Article: 6.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2013] [Revised: 06/28/2013] [Accepted: 07/03/2013] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND AND PURPOSE Endocannabinoid signalling has been shown to have a role in the control of epidermal physiology, whereby anandamide is able to regulate the expression of skin differentiation genes through DNA methylation. Here, we investigated the possible epigenetic regulation of these genes by several phytocannabinoids, plant-derived cannabinoids that have the potential to be novel therapeutics for various human diseases. EXPERIMENTAL APPROACH The effects of cannabidiol, cannabigerol and cannabidivarin on the expression of skin differentiation genes keratins 1 and 10, involucrin and transglutaminase 5, as well as on DNA methylation of keratin 10 gene, were investigated in human keratinocytes (HaCaT cells). The effects of these phytocannabinoids on global DNA methylation and the activity and expression of four major DNA methyltransferases (DNMT1, 3a, 3b and 3L) were also examined. KEY RESULTS Cannabidiol and cannabigerol significantly reduced the expression of all the genes tested in differentiated HaCaT cells, by increasing DNA methylation of keratin 10 gene, but cannabidivarin was ineffective. Remarkably, cannabidiol reduced keratin 10 mRNA through a type-1 cannabinoid (CB1 ) receptor-dependent mechanism, whereas cannabigerol did not affect either CB1 or CB2 receptors of HaCaT cells. In addition, cannabidiol, but not cannabigerol, increased global DNA methylation levels by selectively enhancing DNMT1 expression, without affecting DNMT 3a, 3b or 3L. CONCLUSIONS AND IMPLICATIONS These findings show that the phytocannabinoids cannabidiol and cannabigerol are transcriptional repressors that can control cell proliferation and differentiation. This indicates that they (especially cannabidiol) have the potential to be lead compounds for the development of novel therapeutics for skin diseases.
Collapse
Affiliation(s)
- Mariangela Pucci
- Department of Biomedical Sciences, University of Teramo, Teramo, Italy
| | | | | | | | | | | |
Collapse
|
80
|
Toniolo EF, Maique ET, Ferreira WA, Heimann AS, Ferro ES, Ramos-Ortolaza DL, Miller L, Devi LA, Dale CS. Hemopressin, an inverse agonist of cannabinoid receptors, inhibits neuropathic pain in rats. Peptides 2014; 56:125-31. [PMID: 24703998 PMCID: PMC4112957 DOI: 10.1016/j.peptides.2014.03.016] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2014] [Revised: 03/19/2014] [Accepted: 03/21/2014] [Indexed: 01/05/2023]
Abstract
Direct-acting cannabinoid receptor ligands are well known to reduce hyperalgesic responses after nerve injury, although their psychoactive side effects have damped enthusiasm for their therapeutic development. Hemopressin (Hp) is a nonapeptide that selectively binds CB1 cannabinoid receptors (CB1 receptors) and exerts antinociceptive action in inflammatory pain models. We investigated the effect of Hp on neuropathic pain in rats subjected to chronic constriction injury (CCI) of the sciatic nerve, and explored the mechanisms involved. Oral administration of Hp inhibits mechanical hyperalgesia of CCI-rats up to 6h. Hp treatment also decreases Egr-1 immunoreactivity (Egr-1Ir) in the superficial layer of the dorsal horn of the spinal cord of CCI rats. The antinociceptive effect of Hp seems to be independent of inhibitory descending pain pathway since methysergide (5HT1A receptor antagonist) and yohimbine (α-2 adrenergic receptor antagonist) were unable to prevent Hp antinociceptive effect. Hp decreased calcium flux on DRG neurons from CCI rats, similarly to that observed for AM251, a CB1 receptor antagonist. We also investigated the effect of Hp on potassium channels of CCI rats using UCL 1684 (a blocker of Ca(2+)-activated K(+) channels) which reversed Hp-induced antinociception. Furthermore, concomitant administration of URB-584 (FAAH inhibitor) but not JZL-184 (MAGL inhibitor) potentiates antinociceptive effect of Hp in CCI rats indicating an involvement of anadamide on HP-induced antinociception. Together, these data demonstrate that Hp displays antinociception in pain from neuropathic etiology through local effects. The release of anandamide and the opening of peripheral K(+) channels are involved in the antinociceptive effect.
Collapse
Affiliation(s)
- Elaine F Toniolo
- Laboratory of Neuromodulation and Experimental Pain, Hospital Sírio-Libanês, São Paulo, Brazil
| | - Estêfani T Maique
- Laboratory of Neuromodulation and Experimental Pain, Hospital Sírio-Libanês, São Paulo, Brazil
| | - Wilson A Ferreira
- Department of Pharmacology, University of São Paulo, São Paulo, Brazil
| | | | - Emer S Ferro
- Department of Pharmacology, University of São Paulo, São Paulo, Brazil
| | - Dinah L Ramos-Ortolaza
- Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, USA
| | - Lydia Miller
- Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, USA
| | - Lakshmi A Devi
- Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, USA
| | - Camila S Dale
- Laboratory of Neuromodulation and Experimental Pain, Department of Anatomy, University of São Paulo, São Paulo, Brazil.
| |
Collapse
|
81
|
Ottria R, Ravelli A, Gigli F, Ciuffreda P. Simultaneous ultra-high performance liquid chromathograpy-electrospray ionization-quadrupole-time of flight mass spectrometry quantification of endogenous anandamide and related N-acylethanolamides in bio-matrices. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 958:83-9. [DOI: 10.1016/j.jchromb.2014.03.019] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2013] [Revised: 03/10/2014] [Accepted: 03/16/2014] [Indexed: 10/25/2022]
|
82
|
Pascual AC, Gaveglio VL, Giusto NM, Pasquaré SJ. Cannabinoid receptor-dependent metabolism of 2-arachidonoylglycerol during aging. Exp Gerontol 2014; 55:134-42. [PMID: 24768821 DOI: 10.1016/j.exger.2014.04.008] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/06/2014] [Revised: 03/27/2014] [Accepted: 04/16/2014] [Indexed: 01/23/2023]
Abstract
2-Arachidonoylglycerol (2-AG) is one of the principal endocannabinoids involved in the protection against neurodegenerative processes. Cannabinoids primarily interact with the seven-segment transmembrane cannabinoid receptor 1 (CB1) and cannabinoid receptor 2 (CB2), both of which are expressed in the central nervous system (CNS). The level of 2-AG is controlled through key enzymes responsible for its synthesis or degradation. We have previously observed a deregulation of 2-AG metabolism in physiological aging. The aim of this study was to analyze how 2-AG metabolism is modulated by CB1/CB2 receptors during aging. To this end, both CB1 and CB2 receptor expression and the enzymatic activities (diacylglycerol lipase (DAGL), lysophosphatidate phosphohydrolase (LPAase) and monoacylglycerol lipase (MAGL)) involved in 2-AG metabolism were analyzed in the presence of cannabinoid receptor (CBR) agonists (WIN and JWH) and/or antagonists (SR1 and SR2) in synaptosomes from adult and aged rat cerebral cortex (CC). Our results demonstrate that: (a) aging decreases the expression of both CBRs; (b) LPAase inhibition, due to the individual action of SR1 or SR2, is reverted in the presence of both antagonists together; (c) LPAase activity is regulated mainly by the CB1 receptor in adult and in aged synaptosomes while the CB2 receptor acquires importance when CB1 is blocked; (d) modulation via CBRs of DAGL and MAGL by both antagonists occurs only in aged synaptosomes, stimulating DAGL and inhibiting MAGL activities; (e) only DAGL stimulation is reverted by WIN. Taken together, the results of the present study show that CB1 and/or CB2 receptor antagonists trigger a significant modulation of 2-AG metabolism, underlining their relevance as therapeutic strategy for controlling endocannabinoid levels in physiological aging.
Collapse
MESH Headings
- Aging/metabolism
- Animals
- Arachidonic Acids/metabolism
- Cell Membrane/metabolism
- Cerebral Cortex/metabolism
- Endocannabinoids/metabolism
- Glycerides/metabolism
- Lipoprotein Lipase/metabolism
- Monoacylglycerol Lipases/metabolism
- Phosphatidate Phosphatase/metabolism
- Rats
- Rats, Wistar
- Receptor, Cannabinoid, CB1/agonists
- Receptor, Cannabinoid, CB1/antagonists & inhibitors
- Receptor, Cannabinoid, CB1/metabolism
- Receptor, Cannabinoid, CB2/agonists
- Receptor, Cannabinoid, CB2/antagonists & inhibitors
- Receptor, Cannabinoid, CB2/metabolism
- Receptors, Cannabinoid/metabolism
- Receptors, Cannabinoid/physiology
- Synaptosomes/metabolism
Collapse
Affiliation(s)
- Ana C Pascual
- Instituto de Investigaciones Bioquímicas de Bahía Blanca, Universidad Nacional del Sur - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Edificio E1. Camino La Carrindanga Km 7, 8000 Bahía Blanca, Argentina
| | - Virginia L Gaveglio
- Instituto de Investigaciones Bioquímicas de Bahía Blanca, Universidad Nacional del Sur - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Edificio E1. Camino La Carrindanga Km 7, 8000 Bahía Blanca, Argentina
| | - Norma M Giusto
- Instituto de Investigaciones Bioquímicas de Bahía Blanca, Universidad Nacional del Sur - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Edificio E1. Camino La Carrindanga Km 7, 8000 Bahía Blanca, Argentina
| | - Susana J Pasquaré
- Instituto de Investigaciones Bioquímicas de Bahía Blanca, Universidad Nacional del Sur - Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Edificio E1. Camino La Carrindanga Km 7, 8000 Bahía Blanca, Argentina.
| |
Collapse
|
83
|
Basavarajappa BS, Nagre NN, Xie S, Subbanna S. Elevation of endogenous anandamide impairs LTP, learning, and memory through CB1 receptor signaling in mice. Hippocampus 2014; 24:808-18. [PMID: 24648181 DOI: 10.1002/hipo.22272] [Citation(s) in RCA: 73] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/17/2014] [Indexed: 12/17/2022]
Abstract
In rodents, many exogenous and endogenous cannabinoids, such as anandamide (AEA) and 2-arachidonyl glycerol (2-AG), have been shown to play an important role in certain hippocampal memory processes. However, the mechanisms by which endogenous AEA regulate this processes are not well understood. Here the effects of AEA on long-term potentiation (LTP), hippocampal-dependent learning and memory tasks, pERK1/2, pCaMKIV, and pCREB signaling events in both cannabinoid receptor type 1 (CB1R) wild-type (WT) and knockout (KO) mice were assessed following administration of URB597, an inhibitor of the fatty acid amide hydrolase (FAAH). Acute administration of URB597 enhanced AEA levels without affecting the levels of 2-AG or CB1R in the hippocampus and neocortex as compared to vehicle. In hippocampal slices, URB597 impaired LTP in CB1R WT but not in KO littermates. URB597 impaired object recognition, spontaneous alternation and spatial memory in the Y-maze test in CB1R WT mice but not in KO mice. Furthermore, URB597 enhanced ERK phosphorylation in WT without affecting total ERK levels in WT or KO mice. URB597 impaired CaMKIV and CREB phosphorylation in WT but not in KO mice. CB1R KO mice have a lower pCaMKIV/CaMKIV ratio and higher pCREB/CREB ratio as compared to WT littermates. Our results indicate that pharmacologically elevated AEA impair LTP, learning and memory and inhibit CaMKIV and CREB phosphorylation, via the activation of CB1Rs. Collectively, these findings also suggest that pharmacological elevation of AEA beyond normal concentrations is also detrimental for the underlying physiological responses.
Collapse
Affiliation(s)
- Balapal S Basavarajappa
- Division of Analytical Psychopharmacology, Nathan Kline Institute for Psychiatric Research, Orangeburg, New York; New York State Psychiatric Institute, College of Physicians & Surgeons, Columbia University, New York, New York; Department of Psychiatry, College of Physicians & Surgeons, Columbia University, New York, New York
| | | | | | | |
Collapse
|
84
|
Rapino C, Battista N, Bari M, Maccarrone M. Endocannabinoids as biomarkers of human reproduction. Hum Reprod Update 2014; 20:501-16. [PMID: 24516083 DOI: 10.1093/humupd/dmu004] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND Infertility is a condition of the reproductive system that affects ∼10-15% of couples attempting to conceive a baby. More than half of all cases of infertility are a result of female conditions, while the remaining cases can be attributed to male factors, or to a combination of both. The search for suitable biomarkers of pregnancy outcome is a challenging issue in human reproduction, aimed at identifying molecules with predictive significance of the reproductive potential of male and female gametes. Among the various candidates, endocannabinoids (eCBs), and in particular anandamide (AEA), represent potential biomarkers of human fertility disturbances. Any perturbation of the balance between synthesis and degradation of eCBs will result in local changes of their tone in human female and male reproductive tracts, which in turn regulates various pathophysiological processes, oocyte and sperm maturation included. METHODS PubMed and Web of Science databases were searched for papers using relevant keywords like 'biomarker', 'endocannabinoid', 'infertility', 'pregnancy' and 'reproduction'. RESULTS In this review, we discuss different studies on the measurements of AEA and related eCBs in human reproductive cells, tissues and fluids, where the local contribution of these bioactive lipids could be critical in ensuring normal sperm fertilizing ability and pregnancy. CONCLUSION Based on the available data, we suggest that the AEA tone has the potential to be exploited as a novel diagnostic biomarker of infertility, to be used in association with assays of conventional hormones (e.g. progesterone, β-chorionic gonadotrophin) and semen analysis. However further quantitative research of its predictive capacity is required.
Collapse
Affiliation(s)
- Cinzia Rapino
- Faculty of Veterinary Medicine, University of Teramo, Teramo, Italy StemTeCh Group, Chieti, Italy
| | - Natalia Battista
- Faculty of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, Teramo, Italy European Center for Brain Research/IRCCS Santa Lucia Foundation, Rome, Italy
| | - Monica Bari
- European Center for Brain Research/IRCCS Santa Lucia Foundation, Rome, Italy Department of Experimental Medicine and Surgery, Tor Vergata University of Rome, Rome, Italy
| | - Mauro Maccarrone
- European Center for Brain Research/IRCCS Santa Lucia Foundation, Rome, Italy Center of Integrated Research, Campus Bio-Medico University of Rome, Rome, Italy
| |
Collapse
|
85
|
Sousa-Valente J, Varga A, Ananthan K, Khajuria A, Nagy I. Anandamide in primary sensory neurons: too much of a good thing? Eur J Neurosci 2014; 39:409-18. [DOI: 10.1111/ejn.12467] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2013] [Revised: 11/22/2013] [Accepted: 12/02/2013] [Indexed: 01/01/2023]
Affiliation(s)
- João Sousa-Valente
- Section of Anaesthetics, Pain Medicine and Intensive Care; Department of Surgery and Cancer; Imperial College London; 369 Fulham Road London SW10 9NH UK
| | - Angelika Varga
- Section of Anaesthetics, Pain Medicine and Intensive Care; Department of Surgery and Cancer; Imperial College London; 369 Fulham Road London SW10 9NH UK
| | - Kajaluxy Ananthan
- Section of Anaesthetics, Pain Medicine and Intensive Care; Department of Surgery and Cancer; Imperial College London; 369 Fulham Road London SW10 9NH UK
| | - Ankur Khajuria
- Section of Anaesthetics, Pain Medicine and Intensive Care; Department of Surgery and Cancer; Imperial College London; 369 Fulham Road London SW10 9NH UK
| | - Istvan Nagy
- Section of Anaesthetics, Pain Medicine and Intensive Care; Department of Surgery and Cancer; Imperial College London; 369 Fulham Road London SW10 9NH UK
| |
Collapse
|
86
|
Di Marzo V. Endocannabinoid pathways and their role in multiple sclerosis-related muscular dysfunction. Expert Rev Neurother 2014; 11:9-14. [DOI: 10.1586/ern.11.26] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
87
|
Rea K, Olango WM, Okine BN, Madasu MK, McGuire IC, Coyle K, Harhen B, Roche M, Finn DP. Impaired endocannabinoid signalling in the rostral ventromedial medulla underpins genotype-dependent hyper-responsivity to noxious stimuli. Pain 2014; 155:69-79. [DOI: 10.1016/j.pain.2013.09.012] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2013] [Revised: 08/18/2013] [Accepted: 09/09/2013] [Indexed: 12/20/2022]
|
88
|
Brain regional cannabinoid CB1 receptor signalling and alternative enzymatic pathways for 2-arachidonoylglycerol generation in brain sections of diacylglycerol lipase deficient mice. Eur J Pharm Sci 2014; 51:87-95. [DOI: 10.1016/j.ejps.2013.08.035] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/22/2013] [Revised: 07/19/2013] [Accepted: 08/26/2013] [Indexed: 11/22/2022]
|
89
|
Gomes I, Fujita W, Chandrakala MV, Devi LA. Disease-specific heteromerization of G-protein-coupled receptors that target drugs of abuse. PROGRESS IN MOLECULAR BIOLOGY AND TRANSLATIONAL SCIENCE 2013; 117:207-65. [PMID: 23663971 DOI: 10.1016/b978-0-12-386931-9.00009-x] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/22/2022]
Abstract
Drugs of abuse such as morphine or marijuana exert their effects through the activation of G-protein-coupled receptors (GPCRs), the opioid and cannabinoid receptors, respectively. Moreover, interactions between either of these receptors have been shown to be involved in the rewarding effects of drugs of abuse. Recent advances in the field, using a variety of approaches, have demonstrated that many GPCRs, including opioid, cannabinoid, and dopamine receptors, can form associations between different receptor subtypes or with other GPCRs to form heteromeric complexes. The formation of these complexes, in turn, leads to the modulation of the properties of individual protomers. The development of tools that can selectively disrupt GPCR heteromers as well as monoclonal antibodies that can selectively block signaling by specific heteromer pairs has indicated that heteromers involving opioid, cannabinoid, or dopamine receptors may play a role in various disease states. In this review, we describe evidence for opioid, cannabinoid, and dopamine receptor heteromerization and the potential role of GPCR heteromers in pathophysiological conditions.
Collapse
Affiliation(s)
- Ivone Gomes
- Department of Pharmacology and Systems Therapeutics, Mount Sinai School of Medicine, New York, USA
| | | | | | | |
Collapse
|
90
|
The gastric CB1 receptor modulates ghrelin production through the mTOR pathway to regulate food intake. PLoS One 2013; 8:e80339. [PMID: 24303008 PMCID: PMC3841176 DOI: 10.1371/journal.pone.0080339] [Citation(s) in RCA: 50] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2013] [Accepted: 10/02/2013] [Indexed: 01/11/2023] Open
Abstract
Over the years, the knowledge regarding the relevance of the cannabinoid system to the regulation of metabolism has grown steadily. A central interaction between the cannabinoid system and ghrelin has been suggested to regulate food intake. Although the stomach is the main source of ghrelin and CB1 receptor expression in the stomach has been described, little information is available regarding the possible interaction between the gastric cannabinoid and ghrelin systems in the integrated control of energy homeostasis. The main objective of the present work was to assess the functional interaction between these two systems in terms of food intake using a combination of in vivo and in vitro approaches. The present work demonstrates that the peripheral blockade of the CB1 receptor by rimonabant treatment decreased food intake but only in food-deprived animals. This anorexigenic effect is likely a consequence of decreases in gastric ghrelin secretion induced by the activation of the mTOR/S6K1 intracellular pathway in the stomach following treatment with rimonabant. In support of this supposition, animals in which the mTOR/S6K1 intracellular pathway was blocked by chronic rapamycin treatment, rimonabant had no effect on ghrelin secretion. Vagal communication may also be involved because rimonabant treatment was no longer effective when administered to animals that had undergone surgical vagotomy. In conclusion, to the best of our knowledge, the present work is the first to describe a CB1 receptor-mediated mechanism that influences gastric ghrelin secretion and food intake through the mTOR pathway.
Collapse
|
91
|
Yasuo S, Fischer C, Bojunga J, Iigo M, Korf HW. 2-Arachidonoyl glycerol sensitizes the pars distalis and enhances forskolin-stimulated prolactin secretion in Syrian hamsters. Chronobiol Int 2013; 31:337-42. [DOI: 10.3109/07420528.2013.852104] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
92
|
Depressive behavior in the forced swim test can be induced by TRPV1 receptor activity and is dependent on NMDA receptors. Pharmacol Res 2013; 79:21-7. [PMID: 24200896 DOI: 10.1016/j.phrs.2013.10.006] [Citation(s) in RCA: 45] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2013] [Revised: 10/24/2013] [Accepted: 10/25/2013] [Indexed: 12/31/2022]
Abstract
Blocking, desensitizing, or knocking out transient receptor potential vanilloid type 1 (TRPV1) receptors decreases immobility in the forced swim test, a measure of depressive behavior. We questioned whether enhancing TRPV1 activity promotes immobility in a fashion that is prevented by antidepressants. To test this we activated heat-sensitive TRPV1 receptors in mice by water that is warmer than body temperature (41 °C) or a low dose of resiniferatoxin (RTX). Water at 41 °C elicited less immobility than cooler water (26 °C), indicating that thermoregulatory sites do not contribute to immobility. Although a desensitizing regimen of RTX (3-5 injections of 0.1 mg/kg s.c.) decreased immobility during swims at 26 °C, it did not during swims at 41 °C. In contrast, low dose of RTX (0.02 mg/kg s.c.) enhanced immobility, but only during swims at 41 °C. Thus, activation of TRPV1 receptors, endogenously or exogenously, enhances immobility and these sites are activated by cold rather than warmth. Two distinct types of antidepressants, amitriptyline (10mg/kg i.p.) and ketamine (50 mg/kg i.p.), each inhibited the increase in immobility induced by the low dose of RTX, verifying its mediation by TRPV1 sites. When desensitization was limited to central populations using intrathecal injections of RTX (0.25 μg/kg i.t.), immobility was attenuated at both temperatures and the increase in immobility produced by the low dose of RTX was inhibited. This demonstrates a role for central TRPV1 receptors in depressive behavior, activated by conditions (cold stress) distinct from those that activate TRPV1 receptors along thermosensory afferents (heat).
Collapse
|
93
|
Massi P, Solinas M, Cinquina V, Parolaro D. Cannabidiol as potential anticancer drug. Br J Clin Pharmacol 2013; 75:303-12. [PMID: 22506672 DOI: 10.1111/j.1365-2125.2012.04298.x] [Citation(s) in RCA: 142] [Impact Index Per Article: 12.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
Over the past years, several lines of evidence support an antitumourigenic effect of cannabinoids including Δ(9)-tetrahydrocannabinol (Δ(9)-THC), synthetic agonists, endocannabinoids and endocannabinoid transport or degradation inhibitors. Indeed, cannabinoids possess anti-proliferative and pro-apoptotic effects and they are known to interfere with tumour neovascularization, cancer cell migration, adhesion, invasion and metastasization. However, the clinical use of Δ(9)-THC and additional cannabinoid agonists is often limited by their unwanted psychoactive side effects, and for this reason interest in non-psychoactive cannabinoid compounds with structural affinity for Δ(9)-THC, such as cannabidiol (CBD), has substantially increased in recent years. The present review will focus on the efficacy of CBD in the modulation of different steps of tumourigenesis in several types of cancer and highlights the importance of exploring CBD/CBD analogues as alternative therapeutic agents.
Collapse
Affiliation(s)
- Paola Massi
- Department of Pharmacology, Chemotherapy and Toxicology, University of Milan, Milan, Italy
| | | | | | | |
Collapse
|
94
|
The endocannabinoid signaling system in cancer. Trends Pharmacol Sci 2013; 34:273-82. [PMID: 23602129 DOI: 10.1016/j.tips.2013.03.003] [Citation(s) in RCA: 131] [Impact Index Per Article: 11.9] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Revised: 03/07/2013] [Accepted: 03/12/2013] [Indexed: 12/21/2022]
Abstract
Changes in lipid metabolism are intimately related to cancer. Several classes of bioactive lipids play roles in the regulation of signaling pathways involved in neoplastic transformation and tumor growth and progression. The endocannabinoid system, comprising lipid-derived endocannabinoids, their G-protein-coupled receptors (GPCRs), and the enzymes for their metabolism, is emerging as a promising therapeutic target in cancer. This report highlights the main signaling pathways for the antitumor effects of the endocannabinoid system in cancer and its basic role in cancer pathogenesis, and discusses the alternative view of cannabinoid receptors as tumor promoters. We focus on new players in the antitumor action of the endocannabinoid system and on emerging crosstalk among cannabinoid receptors and other membrane or nuclear receptors involved in cancer. We also discuss the enzyme MAGL, a key player in endocannabinoid metabolism that was recently recognized as a marker of tumor lipogenic phenotype.
Collapse
|
95
|
Siniscalco D, Sapone A, Giordano C, Cirillo A, de Magistris L, Rossi F, Fasano A, Bradstreet JJ, Maione S, Antonucci N. Cannabinoid Receptor Type 2, but not Type 1, is Up-Regulated in Peripheral Blood Mononuclear Cells of Children Affected by Autistic Disorders. J Autism Dev Disord 2013; 43:2686-95. [DOI: 10.1007/s10803-013-1824-9] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
96
|
Puighermanal E, Busquets-Garcia A, Maldonado R, Ozaita A. Cellular and intracellular mechanisms involved in the cognitive impairment of cannabinoids. Philos Trans R Soc Lond B Biol Sci 2013; 367:3254-63. [PMID: 23108544 DOI: 10.1098/rstb.2011.0384] [Citation(s) in RCA: 73] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022] Open
Abstract
Exogenous cannabinoids, such as delta9-tetrahydrocannabinol (THC), as well as the modulation of endogenous cannabinoids, affect cognitive function through the activation of cannabinoid receptors. Indeed, these compounds modulate a number of signalling pathways critically implicated in the deleterious effect of cannabinoids on learning and memory. Thus, the involvement of the mammalian target of rapamycin pathway and extracellular signal-regulated kinases, together with their consequent regulation of cellular processes such as protein translation, play a critical role in the amnesic-like effects of cannabinoids. In this study, we summarize the cellular and molecular mechanisms reported in the modulation of cognitive function by the endocannabinoid system.
Collapse
Affiliation(s)
- Emma Puighermanal
- Departament de Ciències Experimentals i de la Salut, Facultat de Ciències de la Salut i de la Vida, Universitat Pompeu Fabra, Barcelona, Spain
| | | | | | | |
Collapse
|
97
|
Micale V, Di Marzo V, Sulcova A, Wotjak CT, Drago F. Endocannabinoid system and mood disorders: Priming a target for new therapies. Pharmacol Ther 2013; 138:18-37. [DOI: 10.1016/j.pharmthera.2012.12.002] [Citation(s) in RCA: 159] [Impact Index Per Article: 14.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
|
98
|
Liquid chromatography–tandem mass spectrometry analysis of free and esterified fatty acid N-acyl ethanolamines in plasma and blood cells. Anal Biochem 2013. [DOI: 10.1016/j.ab.2012.11.008] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
99
|
Miyamoto S, Jarskog LF, Fleischhacker WW. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials. Curr Opin Psychiatry 2013; 26:158-65. [PMID: 23286991 DOI: 10.1097/yco.0b013e32835d8296] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
PURPOSE OF REVIEW The current article provides a brief review of the clinical efficacy and safety outcomes from selected phase I and II clinical trials of compounds in development acting on targets beyond the dopamine D2 receptor in patients with schizophrenia. RECENT FINDINGS A number of experimental pharmacological targets have been studied in clinical trials. Among those, glutamatergic and nicotinergic pathways have received most attention. Glycine transporter 1 inhibitors used adjunctively with antipsychotics suggest efficacy for negative symptoms of schizophrenia. Adjunctive alpha7 nicotinic acetylcholine receptor agonists and minocycline may improve negative symptoms and cognitive deficits. Adjunctive oxytocin may benefit psychotic symptoms and social cognitive deficits. Adjunctive erythropoietin may improve cognitive function. SUMMARY Experimental therapeutic research for schizophrenia is rapidly expanding and a number of compounds with novel mechanisms of action are demonstrating encouraging evidence for efficacy across a range of symptoms. However, much work still needs to be conducted before these new agents can be considered for routine clinical treatment. In particular, further assessment of efficacy and longer term safety and tolerability monitoring are required.
Collapse
Affiliation(s)
- Seiya Miyamoto
- Department of Neuropsychiatry, St Marianna University School of Medicine, 2-16-1, Sugao, Miyamae-ku, Kawasaki, Kanagawa 216-8511, Japan.
| | | | | |
Collapse
|
100
|
Zogopoulos P, Vasileiou I, Patsouris E, Theocharis S. The neuroprotective role of endocannabinoids against chemical-induced injury and other adverse effects. J Appl Toxicol 2013; 33:246-64. [DOI: 10.1002/jat.2828] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2012] [Revised: 08/31/2012] [Accepted: 09/01/2012] [Indexed: 12/21/2022]
Affiliation(s)
- Panagiotis Zogopoulos
- 1st Department of Pathology, Medical School; National and Kapodistrian University of Athens; Athens; Greece
| | - Ioanna Vasileiou
- 1st Department of Pathology, Medical School; National and Kapodistrian University of Athens; Athens; Greece
| | - Efstratios Patsouris
- 1st Department of Pathology, Medical School; National and Kapodistrian University of Athens; Athens; Greece
| | - Stamatios Theocharis
- 1st Department of Pathology, Medical School; National and Kapodistrian University of Athens; Athens; Greece
| |
Collapse
|